Anesiva (Nasdaq: ANSV) is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management.
Our marketed product, Zingo™, is indicated for use on intact skin to provide topical local pain reduction before blood draws or peripheral IV starts in children ages three to 18. Our second product, Adlea™, is in two pivotal Phase 3 trials in support of an indication for the management of acute pain following orthopedic surgery. Adlea has been shown in Phase 2 trials to reduce pain for weeks to months in patients suffering from both acute and chronic moderate to severe pain after a single, localized administration.
 |
Zingo™ – A FAST ACTING LOCAL ANESTHETIC NOW AVAILABLE! Zingo has been shown to provide local analgesia in 1 to 3 minutes prior to peripheral IV starts and blood draws in children three to 18 years of age. In clinical trials, the most common adverse reactions were redness (erythema), red dots (petechiae) and swelling (edema) at the site of administration. Learn more Visit www.Zingo.com |
